+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Non-infectious Macular Edema Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 323 Pages
  • January 2024
  • Region: Global
  • Fairfield Market Research
  • ID: 5925029
Description Jump to:
A groundbreaking study has shed light on a remarkable development in the global non-infectious macular edema treatment market. The surge in diabetes-related complications and increased awareness of eye-related ailments across various regions have fueled a growing demand for effective treatments for macular edema. This surge in demand has led to a proliferation of treatment options in the market, including Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics, and more. Anti-VEGF treatments have traditionally dominated the market, and they are expected to maintain the highest market share during the forecast period.

Transition Away from Anti-VEGF Toward Corticosteroids

However, the Anti-VEGF market is anticipated to witness a gradual decline in usage due to heightened awareness of potential side effects associated with the drug. Systemic immunomodulatory treatment is poised to reduce reliance on Anti-VEGF medications. Notably, Corticosteroids are projected to experience an exceptional surge in demand in the coming years, with the market expected to grow at a stellar rate during the forecast period.

Intravitreal Implants and Immunosuppressants Triggering Market Growth

The recent approval of Intravitreal Implants for macular edema treatment has catalyzed market growth. The introduction of three new products – Eylea, Ozurdex, and Iluvien – has led to increased adoption of intravitreal medications, particularly in North America. Intravitreally injected medications were less commonly used in North America and European countries, where laser photocoagulation was the primary treatment method before the launch of Lucentis in 2012.

The rising adoption of Intravitreal therapies can be attributed to the availability of low-dose, high-efficacy corticosteroid implants for Intravitreal use. Patients are increasingly turning to Intravitreal implants, driving global demand for macular edema treatment.

Immunosuppressant Therapies Enhance Treatment Efficacy

Immunosuppressant therapies, often used in conjunction with corticosteroids, play a vital role in the treatment of macular edema. These therapies are typically added to corticosteroid regimens to reduce the need for high doses of systemic steroids or used independently as steroid-sparing agents when steroid treatment is not well-tolerated.

For example, three immunomodulators – methotrexate (Rheumatrex), azathioprine (Imuran), and mycophenolate mofetil (MMF, Cellcept) – have proven to be highly effective in achieving disease quiescence and are well-tolerated by patients. These immunosuppressants have emerged as efficient treatment options, driving demand in the global market for non-infectious macular edema treatment.

Challenges in the Global Macular Edema Market

While the market exhibits significant growth potential, challenges persist. Many patients and ophthalmologists opt for alternative treatments over Anti-VEGF and corticosteroids due to the repeated injections and high costs associated with these drugs. Non-compliance with treatment schedules, resulting in missed injections, can lead to irreversible damage and permanent vision loss in diabetic macular edema (DME) patients.

Additionally, counterfeit and off-label drugs are readily available in the global market. The launch of biosimilars for some blockbuster anti-VEGF agents is expected to further impact the market by reducing opportunities for branded and patented drugs.

Market Segmentation

Drug Type
  • Anti-VEGF
  • Corticosteroids
  • Immunosuppressant
  • Biologics
  • Others
Indication
  • Non-infectious Uveitic Macular Edema
  • Diabetic Macular Edema
  • Retinal Vein Occlusion with Macular Edema
Route of Administration
  • Oral
  • Parenteral
  • Topical
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Region
  • North America
  • Latin America
  • Europe
  • Japan
  • MEA
  • APAC


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Non-infectious Macular Edema Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Production Output and Trade Statistics, 2018 - 2023
3.1. Global Non-infectious Macular Edema Treatment Market Production Output, by Region, Value (US$ Mn), 2018 - 2023
3.1.1. North America
3.1.2. Europe
3.1.3. Asia Pacific
3.1.4. Latin America
3.1.5. Middle East and Africa
4. Price Analysis, 2018 - 2023
4.1. Global Average Price Analysis, by Drug Type/ Material, US$ Per Unit, 2018 - 2023
4.2. Prominent Factor Affecting Non-infectious Macular Edema Treatment Prices
4.3. Global Average Price Analysis, by Region, US$ Per Unit
5. Global Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031
5.1. Global Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Anti-VEGF
5.1.1.2. Corticosteroids
5.1.1.3. Immunosuppressant
5.1.1.4. Biologics
5.1.1.5. Others
5.2. Global Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Non-infectious Uveitic Macular Edema
5.2.1.2. Diabetic Macular Edema
5.2.1.3. Retinal Vein Occlusion with Macular Edema
5.3. Global Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Oral
5.3.1.2. Parenteral
5.3.1.3. Topical
5.4. Global Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Hospital Pharmacies
5.4.1.2. Retail Pharmacies
5.4.1.3. Online Pharmacies
5.5. Global Non-infectious Macular Edema Treatment Market Outlook, by Region, Value (US$ Mn) and Volume, 2018 - 2031
5.5.1. Key Highlights
5.5.1.1. North America
5.5.1.2. Europe
5.5.1.3. Asia Pacific
5.5.1.4. Latin America
5.5.1.5. Middle East & Africa
6. North America Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031
6.1. North America Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Anti-VEGF
6.1.1.2. Corticosteroids
6.1.1.3. Immunosuppressant
6.1.1.4. Biologics
6.1.1.5. Others
6.2. North America Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Non-infectious Uveitic Macular Edema
6.2.1.2. Diabetic Macular Edema
6.2.1.3. Retinal Vein Occlusion with Macular Edema
6.3. North America Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Oral
6.3.1.2. Parenteral
6.3.1.3. Topical
6.4. North America Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. Hospital Pharmacies
6.4.1.2. Retail Pharmacies
6.4.1.3. Online Pharmacies
6.5. North America Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
6.5.1. Key Highlights
6.5.1.1. U.S. Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
6.5.1.2. U.S. Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
6.5.1.3. U.S. Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
6.5.1.4. U.S. Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
6.5.1.5. Canada Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
6.5.1.6. Canada Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
6.5.1.7. Canada Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
6.5.1.8. Canada Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Europe Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031
7.1. Europe Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Anti-VEGF
7.1.1.2. Corticosteroids
7.1.1.3. Immunosuppressant
7.1.1.4. Biologics
7.1.1.5. Others
7.2. Europe Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Non-infectious Uveitic Macular Edema
7.2.1.2. Diabetic Macular Edema
7.2.1.3. Retinal Vein Occlusion with Macular Edema
7.3. Europe Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Oral
7.3.1.2. Parenteral
7.3.1.3. Topical
7.4. Europe Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Hospital Pharmacies
7.4.1.2. Retail Pharmacies
7.4.1.3. Online Pharmacies
7.5. Europe Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1. Key Highlights
7.5.1.1. Germany Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.2. Germany Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.3. Germany Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.4. Germany Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.5. U.K. Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.6. U.K. Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.7. U.K. Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.8. U.K. Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.9. France Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.10. France Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.11. France Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.12. France Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.13. Italy Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.14. Italy Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.15. Italy Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.16. Italy Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.17. Turkey Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.18. Turkey Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.19. Turkey Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.20. Turkey Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.21. Russia Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.22. Russia Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.23. Russia Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.24. Russia Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.25. Rest of Europe Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.26. Rest of Europe Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.27. Rest of Europe Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
7.5.1.28. Rest of Europe Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031
8.1. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Anti-VEGF
8.1.1.2. Corticosteroids
8.1.1.3. Immunosuppressant
8.1.1.4. Biologics
8.1.1.5. Others
8.2. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Non-infectious Uveitic Macular Edema
8.2.1.2. Diabetic Macular Edema
8.2.1.3. Retinal Vein Occlusion with Macular Edema
8.3. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Oral
8.3.1.2. Parenteral
8.3.1.3. Topical
8.4. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. Hospital Pharmacies
8.4.1.2. Retail Pharmacies
8.4.1.3. Online Pharmacies
8.5. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1. Key Highlights
8.5.1.1. China Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.2. China Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.3. China Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.4. China Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.5. Japan Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.6. Japan Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.7. Japan Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.8. Japan Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.9. South Korea Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.10. South Korea Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.11. South Korea Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.12. South Korea Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.13. India Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.14. India Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.15. India Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.16. India Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.17. Southeast Asia Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.18. Southeast Asia Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.19. Southeast Asia Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.20. Southeast Asia Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.21. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.22. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.23. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
8.5.1.24. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Latin America Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031
9.1. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
9.1.1. Key Highlights
9.1.1.1. Anti-VEGF
9.1.1.2. Corticosteroids
9.1.1.3. Immunosuppressant
9.1.1.4. Biologics
9.1.1.5. Others
9.2. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
9.2.1. Key Highlights
9.2.1.1. Non-infectious Uveitic Macular Edema
9.2.1.2. Diabetic Macular Edema
9.2.1.3. Retinal Vein Occlusion with Macular Edema
9.3. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
9.3.1. Key Highlights
9.3.1.1. Oral
9.3.1.2. Parenteral
9.3.1.3. Topical
9.4. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
9.4.1. Key Highlights
9.4.1.1. Hospital Pharmacies
9.4.1.2. Retail Pharmacies
9.4.1.3. Online Pharmacies
9.5. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
9.5.1. Key Highlights
9.5.1.1. Brazil Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
9.5.1.2. Brazil Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
9.5.1.3. Brazil Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
9.5.1.4. Brazil Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
9.5.1.5. Mexico Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
9.5.1.6. Mexico Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
9.5.1.7. Mexico Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
9.5.1.8. Mexico Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
9.5.1.9. Argentina Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
9.5.1.10. Argentina Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
9.5.1.11. Argentina Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
9.5.1.12. Argentina Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
9.5.1.13. Rest of Latin America Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
9.5.1.14. Rest of Latin America Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
9.5.1.15. Rest of Latin America Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
9.5.1.16. Rest of Latin America Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
9.5.2. BPS Analysis/Market Attractiveness Analysis
10. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031
10.1. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
10.1.1. Key Highlights
10.1.1.1. Anti-VEGF
10.1.1.2. Corticosteroids
10.1.1.3. Immunosuppressant
10.1.1.4. Biologics
10.1.1.5. Others
10.2. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
10.2.1. Key Highlights
10.2.1.1. Non-infectious Uveitic Macular Edema
10.2.1.2. Diabetic Macular Edema
10.2.1.3. Retinal Vein Occlusion with Macular Edema
10.3. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
10.3.1. Key Highlights
10.3.1.1. Oral
10.3.1.2. Parenteral
10.3.1.3. Topical
10.4. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
10.4.1. Key Highlights
10.4.1.1. Hospital Pharmacies
10.4.1.2. Retail Pharmacies
10.4.1.3. Online Pharmacies
10.5. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1. Key Highlights
10.5.1.1. GCC Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1.2. GCC Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1.3. GCC Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1.4. GCC Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1.5. South Africa Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1.6. South Africa Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1.7. South Africa Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1.8. South Africa Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1.9. Egypt Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1.10. Egypt Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1.11. Egypt Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1.12. Egypt Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1.13. Nigeria Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1.14. Nigeria Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1.15. Nigeria Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1.16. Nigeria Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1.17. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1.18. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1.19. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
10.5.1.20. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
10.5.2. BPS Analysis/Market Attractiveness Analysis
11. Competitive Landscape
11.1. Product vs Indication Heatmap
11.2. Company Market Share Analysis, 2023
11.3. Competitive Dashboard
11.4. Company Profiles
11.4.1. Pfizer, Inc.
11.4.1.1. Company Overview
11.4.1.2. Product Portfolio
11.4.1.3. Financial Overview
11.4.1.4. Business Strategies and Development
11.4.2. Novartis AG
11.4.2.1. Company Overview
11.4.2.2. Product Portfolio
11.4.2.3. Financial Overview
11.4.2.4. Business Strategies and Development
11.4.3. F. Hoffman - La Roche Ltd.
11.4.3.1. Company Overview
11.4.3.2. Product Portfolio
11.4.3.3. Financial Overview
11.4.3.4. Business Strategies and Development
11.4.4. AbbVie Inc
11.4.4.1. Company Overview
11.4.4.2. Product Portfolio
11.4.4.3. Financial Overview
11.4.4.4. Business Strategies and Development
11.4.5. Bayer AG
11.4.5.1. Company Overview
11.4.5.2. Product Portfolio
11.4.5.3. Financial Overview
11.4.5.4. Business Strategies and Development
11.4.6. Valeant Pharmaceuticals Inc
11.4.6.1. Company Overview
11.4.6.2. Product Portfolio
11.4.6.3. Financial Overview
11.4.6.4. Business Strategies and Development
11.4.7. Alimera Sciences Inc
11.4.7.1. Company Overview
11.4.7.2. Product Portfolio
11.4.7.3. Financial Overview
11.4.7.4. Business Strategies and Development
11.4.8. Clearside Biomedical, Inc
11.4.8.1. Company Overview
11.4.8.2. Product Portfolio
11.4.8.3. Financial Overview
11.4.8.4. Business Strategies and Development
12. Appendix
12.1. Research Methodology
12.2. Report Assumptions
12.3. Acronyms and Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Allergan, Plc.
  • Amgen, Inc.
  • Pfizer, Inc.
  • Novartis AG
  • F. Hoffman - La Roche Ltd.
  • AbbVie Inc.
  • Bayer AG
  • Valeant Pharmaceuticals Inc.
  • Alimera Sciences Inc.
  • Clearside Biomedical, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Non-Infectious Macular Edema Treatment - Global Strategic Business Report - Product Image

Non-Infectious Macular Edema Treatment - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Macular Edema and Macular Degeneration Global Market Report 2024 - Product Image

Macular Edema and Macular Degeneration Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Diabetic Macular Edema Treatment - Global Strategic Business Report - Product Image

Diabetic Macular Edema Treatment - Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
Macular Edema Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Macular Edema Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 99 Pages
  • Global
From
Global Diabetic Macular Edema Treatment Market by Treatment (Corticosteroid Injections, Drugs, Laser Treatment), End-User (Hospitals, Ophthalmology Clinics) - Forecast 2024-2030 - Product Image

Global Diabetic Macular Edema Treatment Market by Treatment (Corticosteroid Injections, Drugs, Laser Treatment), End-User (Hospitals, Ophthalmology Clinics) - Forecast 2024-2030

  • Report
  • 198 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.